Results 181 to 190 of about 16,042 (257)

Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials.

Lancet Microbe
Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Ackerman ME, Weiner JA, Modlin J, Arita M, Bandyopadhyay AS, Gast C, Sáez-Llorens X, Rüttimann RW, Van Damme P, De Coster I, Wright PF.   +14 more
europepmc   +1 more source

Expected RATE of Vaccine-Associated Paralytic Poliomyelitis: A Simulation Analysis Regarding Transition from the Trivalent to Bivalent Oral Poliovirus Vaccine.

Int J Prev Med, 2021
Yasri S, Wiwanitkit V.
europepmc   +1 more source

Humoral and Mucosal Immunity in Infants Induced by Three Sequential Inactivated Poliovirus Vaccine-Live Attenuated Oral Poliovirus Vaccine Immunization Schedules [PDF]

, 1997
John F. Modlin, N. A. Halsey, M. L. Thoms, Carlton Meschievitz, P. Patriarca, the Baltimore Area Polio Vaccine Study Group   +5 more
openalex   +1 more source

The Early Evolution of Oral Poliovirus Vaccine Is Shaped by Strong Positive Selection and Tight Transmission Bottlenecks.

Cell Host Microbe, 2021
Valesano AL, Taniuchi M, Fitzsimmons WJ, Islam MO, Ahmed T, Zaman K, Haque R, Wong W, Famulare M, Lauring AS.   +9 more
europepmc   +1 more source

The Double-Edged Sword: How Evolution Can Make or Break a Live-Attenuated Virus Vaccine [PDF]

, 2011

core   +1 more source

Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. [PDF]

NPJ Vaccines, 2020
Konopka-Anstadt JL, Campagnoli R, Vincent A, Shaw J, Wei L, Wynn NT, Smithee SE, Bujaki E, Te Yeh M, Laassri M, Zagorodnyaya T, Weiner AJ, Chumakov K, Andino R, Macadam A, Kew O, Burns CC.   +16 more
europepmc   +1 more source

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2? [PDF]

, 2018
Sonia Resik, Alina Tejeda, Ondrej Mach, Magilé Fonseca, Manuel Dı́az, Nilda Alemañy, Lai Heng Hung, Yoan Alemán‬, Ileana Mesa, Gloria Garcia, Roland W. Sutter   +10 more
openalex   +1 more source

Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. [PDF]

Science, 2020
Macklin GR, O'Reilly KM, Grassly NC, Edmunds WJ, Mach O, Santhana Gopala Krishnan R, Voorman A, Vertefeuille JF, Abdelwahab J, Gumede N, Goel A, Sosler S, Sever J, Bandyopadhyay AS, Pallansch MA, Nandy R, Mkanda P, Diop OM, Sutter RW.   +18 more
europepmc   +1 more source

Poliomyelitis seroprevalence in high risk populations of India before the trivalent-bivalent oral poliovirus vaccine switch in 2016.

Int J Infect Dis, 2021
Ahmad M, Verma H, Kunwar A, Soni S, Sinha U, Gawande M, Sethi R, Nalavade U, Sharma D, Bhatnagar P, Bahl S, Deshpande J.   +11 more
europepmc   +1 more source

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial. [PDF]

Lancet
Ochoge M, Futa AC, Umesi A, Affleck L, Kotei L, Daffeh B, Saidy-Jah E, Njie A, Oyadiran O, Edem B, Jallow M, Jallow E, Donkor SA, Tritama E, Abid T, Jones KAV, Mainou BA, Konz JO, Fix A, Gast C, Clarke E.   +20 more
europepmc   +1 more source